Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.46 |
| ▸ | MYC | P01106 | 2/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CLCN2 | P51788 | 3/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14873777 | 0.84 | HPGD (0.42) | NOTUMMYCNR4A1CTSBTDP1 | |
| SCHEMBL7573655 | 0.84 | NOTUM (0.46) | NOTUMMYCNR4A1CTSBTDP1 | |
| SCHEMBL27544752 | 0.81 | CSNK2A2 (0.49) | NOTUMMYCNR4A1CTSBTDP1 | |
| SCHEMBL20721983 | 0.81 | HPGD (0.55) | NOTUMMYCNR4A1CTSBTDP1 | |
| SCHEMBL18535886 | 0.79 | HSP90AB1 (0.41) | NOTUMSORT1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL5032079 | 0.79 | ABL1 (0.45) | MYCSORT1ALDH1A1TSHRCASP1 | |
| SCHEMBL4670497 | 0.79 | TSHR (0.52) | NOTUMMYCNR4A1CTSBTDP1 | |
| Hydrochloric Acid SCHEMBL9860913 | 0.79 | HPGD (0.53) | NOTUMMYCNR4A1CTSBTDP1 | |
| SCHEMBL107955 | 0.79 | TSHR (0.52) | NOTUMMYCNR4A1CTSBTDP1 | |
| SCHEMBL7822093 | 0.79 | HPGD (0.44) | NOTUMMYCCTSBCLCN2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220280495-A1 | Combination Therapy Including an MDM2 Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of Cancers | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| EP-4039256-A1 | COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND DASATINIB OR NILOTINIB FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA | Amgen Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| US-10881648-B2 | Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | AMGEN INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20190290630-A1 | Combination Therapy Including an MDM2 Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of Cancers | AMGEN, INC. | 2019-09-26 | — | — | US | disclosed |
| EP-2961735-B1 | A BENZOIC ACID DERIVATIVE MDM2 INHIBITOR FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20160287569-A1 | COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. (US) | 2016-10-06 | — | — | US | disclosed |
| EP-3068393-A2 | COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | Amgen Inc. (US) | 2016-09-21 | — | — | EP | disclosed |
| EP-2961735-A1 | A BENZOIC ACID DERIVATIVE MDM2 INHIBITOR FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| WO-2015070224-A2 | COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. (US) | 2015-05-14 | — | — | WO | disclosed |
| US-8952036-B2 | Benzoic acid derivative MDM2 inhibitor for the treatment of cancer | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-7396939-B2 | 3-cyclopropyl-4-(3-amino-2-methylbenzoyl)pyrazoles and their use as herbicides | BAYER CROPSCIENCE GMBH (DE) | 2008-07-08 | — | — | US | disclosed |
| US-7396939-B2 | 3-cyclopropyl-4-(3-amino-2-methylbenzoyl)pyrazoles and their use as herbicides | BAYER CROPSCIENCE GMBH (DE) | 2008-07-08 | — | — | US | disclosed |
| EP-1824338-B1 | 3-CYCLOPROPYL-4-(3-AMINO-2-METHYLBENZOYL)PYRAZOLS AND THE USE OF THE SAME AS HERBICIDES | BAYER CROPSCIENCE AG (DE) | 2008-03-19 | — | — | EP | disclosed |
| US-20060128568-A1 | 3-cyclopropyl-4-(3-amino-2-methylbenzoyl)pyrazoles and their use as herbicides | BAYER CROPSCIENCE GMBH (DE) | 2006-06-15 | — | — | US | disclosed |
| EP-0609798-B1 | 4-Benzoyl isoxazoles and their use as herbicides | AVENTIS AGRICULTURE LTD (GB) | 2002-10-02 | — | — | EP | disclosed |
| EP-0759911-A1 | 4-BENZOYLISOXAZOLE DERIVATIVES AND THEIR USE AS HERBICIDES | RHONE POULENC AGRICULTURE LTD. (GB) | 1997-03-05 | — | — | EP | disclosed |
| WO-1995031446-A1 | 4-BENZOYLISOXAZOLE DERIVATIVES AND THEIR USE AS HERBICIDES | RHONE POULENC AGRICULTURE LTD. (GB) | 1995-11-23 | — | — | WO | disclosed |
| US-5374606-A | Pre- and postemergence | RHONE-POULENC AGRICULTURE LIMITED (GB) | 1994-12-20 | — | — | US | disclosed |
| EP-0609798-A1 | 4-Benzoyl isoxazoles and their use as herbicides | RHONE POULENC AGRICULTURE LTD. (GB) | 1994-08-10 | — | — | EP | disclosed |
| US-5334753-A | Lithiating halobenzoic acid, then reacting with electrophilic reagent | RHONE-POULENC AGRICULTURE LTD (GB) | 1994-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881648-B2 | Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | MDM2, TP53, CDKN1A | NOTUM 2578/4885MYC 16/4885NR4A1 2357/4885 |
| US-20060128568-A1 | 3-cyclopropyl-4-(3-amino-2-methylbenzoyl)pyrazoles and their use as herbicides | CBR3, DDT, CYP1B1 | NOTUM 1055/4885MYC 2548/4885NR4A1 375/4885 |
| US-20190290630-A1 | Combination Therapy Including an MDM2 Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of Cancers | MDM2, TP53, CDKN1A | NOTUM 2578/4885MYC 16/4885NR4A1 2357/4885 |
| US-20220280495-A1 | Combination Therapy Including an MDM2 Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of Cancers | MDM2, TP53, CDKN1A | NOTUM 2578/4885MYC 16/4885NR4A1 2357/4885 |
| US-20160287569-A1 | COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | MDM2, TP53, CDKN1A | NOTUM 2578/4885MYC 16/4885NR4A1 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.